Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06757257
Recruiting Observational

Special Drug Use-results Survey for Long-term Use (Fostamatinib)

NCT06757257 · tracked via the Priya Life Science Japan tracker
Sponsor
Kissei Pharmaceutical Co., Ltd
Phase
Observational
Started
2023-05-29
Last updated
2025-01-03

Condition(s) studied

Chronic Idiopathic Thrombocytopenic Purpura

Investigational drug(s) / intervention(s)

fostamatinib →

fostamatinib: oral administration

Study summary

The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Primary outcome measure(s)

  • Adverse events — 18 months

Trial sites (1)

FacilityCityRegionStatus
Research site Tokyo and Japanese Other Cities Japan Recruiting

More Kissei Pharmaceutical Co., Ltd. trials in Japan

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration Active, not recruiting
Special Drug Use-results Survey for Long-term Use（Avacopan） Recruiting
A Clinical Study of KLH-2109 in Patients With Endometriosis Active, not recruiting
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06757257 on ClinicalTrials.gov ↗ ← All trials in Japan